Difference between revisions of "Team:Madrid-OLM/Entrepreneurship"
| Line 58: | Line 58: | ||
<div class="col-md-8 col-lg-8"> | <div class="col-md-8 col-lg-8"> | ||
<h3>Talking to the future investors: HAX programme</h3> | <h3>Talking to the future investors: HAX programme</h3> | ||
| − | <img class="figureimage | + | <img class="figureimage" alt="Image1" src="https://static.igem.org/mediawiki/2018/b/b6/T--Madrid-OLM--Awards--HAX.png" style="width:80%;"/> |
| − | <p class="lead | + | <p class="lead">We have introduced our project to the leading Hardware accelerator in the world: HAX.</p> |
<p class="lead"><a href="http://hax.co/">HAX</a> is the Hardware branch of the global hedge fund SOSV and it is located in the Silicon Valley of the Hardware, Shenzhen (China). The HAX programme is divided into two stages: </p> | <p class="lead"><a href="http://hax.co/">HAX</a> is the Hardware branch of the global hedge fund SOSV and it is located in the Silicon Valley of the Hardware, Shenzhen (China). The HAX programme is divided into two stages: </p> | ||
<ol class="ourlist"> | <ol class="ourlist"> | ||
| Line 75: | Line 75: | ||
</section> | </section> | ||
| + | <section class="text-center switchable feature-large"> | ||
| + | <div class="container"> | ||
| + | <div class="row justify-content-around boxed boxed--border bg--secondary boxed--lg box-shadow"> | ||
| + | <div class="col-md-8 col-lg-8"> | ||
| + | <h3>Making commercial agreements with Spanish biotech startups</h3> | ||
| + | <img class="figureimage" alt="Image1" src="https://static.igem.org/mediawiki/2018/7/74/T--Madrid-OLM--Awards--Aptus.png" style="width:70%;"/> | ||
| + | <p class="lead">Although we have developed a discovery system for new aptamers, we have established a commercial agreement with an <a href="http://aptusbiotech.com/"></a>Spanish leader on the field, to integrate five of their working aptamers in our initial device.</p> | ||
| + | <p class="lead">This agreement enables us to start implementing our system. Now we can escalate our device to five additional molecules, adding them to our initial protein: OLE1 (the most common allergen in olive pollen). </p> | ||
| + | </div> | ||
| + | </div> | ||
| + | <!--end of row--> | ||
| + | </div> | ||
| + | <!--end of container--> | ||
| + | </section> | ||
Revision as of 20:37, 17 October 2018
Entrepreneurship
When technology meets social needs
The sense of initiative and entrepreneurship should take into account a number of complementary factors. The essence of profitability has many sides, as a dice.
We would love to run fast enough to chase this sort of elegance!
We believe there is an iGEM mindset: any prospective benefits should take into account social improvement, sustainable development goals, and finally, progressive scalability oriented to contribute to humanity as a whole.
We would love to contribute to spreading these ideas as a competitive player in the market. That is why we are founding a startup based on what we have learned last year at iGEM.
Enabling an entrepreneurial network
Within the iGEM competition, we have been generating the business network that we will need to found a challenging and ambitious startup. Our roadmap is categorized into three main sections.
Talking to the future investors: HAX programme
We have introduced our project to the leading Hardware accelerator in the world: HAX.
HAX is the Hardware branch of the global hedge fund SOSV and it is located in the Silicon Valley of the Hardware, Shenzhen (China). The HAX programme is divided into two stages:
The first one where you obtain 100.000$ and a place to work within 6 months in Shenzhen to develop the most suitable manufacturing network for the product.
The second one is based on San Francisco and covers the development of the commercial structure for the startup.
We had applied to HAX and we have been successfully selected for the first stage with the condition that all the biotech subsystems should be developed.
Throughout the iGEM competition, we had proved that our device measures correctly the target protein. Therefore, we had recovered the conversation with HAX.
Once we are back from Boston we will prepare our travel to Shenzhen.
Making commercial agreements with Spanish biotech startups
Although we have developed a discovery system for new aptamers, we have established a commercial agreement with an Spanish leader on the field, to integrate five of their working aptamers in our initial device.
This agreement enables us to start implementing our system. Now we can escalate our device to five additional molecules, adding them to our initial protein: OLE1 (the most common allergen in olive pollen).